Table 1 JakCCANDO HIV patients retain high levels of CMV-reactive antibodies on ART, but cIMT values remain in the normal range

Clinical and demographic features

 Age (years)

32 (18–45)

32 (19–47)

–

0.43^a

–

–

 Sex (M/F)

12/8

30/10

–

0.25^b

–

–

 HIV RNA (Log₁₀ copies/µL)

–

5.0 (2.9–6.4)

0.76 (0–5.0)

–

–

0.0001^c

 CD4 T-cells (cells/µL)

–

68 (2–199)

225 (6–516)

–

–

0.0001

 CMV Lysate antibody (Log₁₀ AU)

3.3 (2.8–4.8)

4.1 (3.2–5.2)

4.3 (3.1–5.2)

0.02^a

0.003^a

0.03

 CMV IE-1 antibody (Log₁₀ AU)

2.3 (1.1–3.8)

2.7 (1.7–3.8)

2.7 (1.2–3.8)

0.10

0.16

0.25

 CRP (µg/mL)

–

1.9 (0.007–50)

2.2 (0.004–54)

–

–

0.97

 sIFNRα/β (ng/mL)

–

4.4 (2.5–8.7)

4.4 (1.8–6.8)

–

–

0.67

 Right cIMT (mm)

< 0.70^d

0.58 (0.39–0.77)

0.57 (0.39–0.77)^e

–

–

0.08

 Left cIMT (mm)

< 0.70^d

0.57 (0.45–0.83)

0.51 (0.32–0.70)

–

–

0.24

NK cell phenotypes

 CD16⁺ (% of CD56^Hi)

58 (23–67)

58 (28–75)

62 (11–81)

0.15

0.06

0.48

 CD16⁺ (% of CD56^Lo)

81 (42–96)

81 (37–95)

80 (48–96)

0.48

0.60

0.24

 LIR1⁺ (% of CD56^Hi)

0.6 (0–1.6)

0.4 (0–4.6)

0.5 (0–10)

0.48

0.59

0.01

 LIR1⁺ (% of CD56^Lo)

1.6 (0.3–5.9)

2.2 (0.06–13)

2.4 (0.2–9.4)

0.19

0.09

0.80

 CD57⁺ (% of CD56^Hi)

7.0 (0.7–29)

4.3 (0.15–34)

4.0 (0.1–22)

0.26

0.10

0.46

 CD57⁺ (% of CD56^Lo)

75 (27–90)

58 (29–89)

60 (18–89)

0.02

0.02

0.23